Calfa, C., Rothe, M., Mangat-Dhaliwal, P., Garrett-Mayer, E., Reynolds, C., Wadlow, R. C., … Schilsky, R. L. (2025). 942P Atezolizumab plus Talazoparib (A+T) in patients (pts) with solid tumors with non-BRCA1/2 DNA damage repair gene (non-BRCA) mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In Annals of Oncology (Vol. 36, pp. S616–S617). Elsevier BV. https://doi.org/10.1016/j.annonc.2025.08.1511

Calfa, C., M. Rothe, P. Mangat-Dhaliwal, E. Garrett-Mayer, C. Reynolds, R. C. Wadlow, M. -. T. D. Chen, et al. “942P Atezolizumab plus Talazoparib (A+T) in patients (pts) with solid tumors with non-BRCA1/2 DNA damage repair gene (non-BRCA) mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” In Annals of Oncology, 36:S616–17. Elsevier BV, 2025. https://doi.org/10.1016/j.annonc.2025.08.1511.

Calfa C, Rothe M, Mangat-Dhaliwal P, Garrett-Mayer E, Reynolds C, Wadlow RC, et al. 942P Atezolizumab plus Talazoparib (A+T) in patients (pts) with solid tumors with non-BRCA1/2 DNA damage repair gene (non-BRCA) mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In: Annals of Oncology. Elsevier BV; 2025. p. S616–7.

Calfa, C., et al. “942P Atezolizumab plus Talazoparib (A+T) in patients (pts) with solid tumors with non-BRCA1/2 DNA damage repair gene (non-BRCA) mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” Annals of Oncology, vol. 36, Elsevier BV, 2025, pp. S616–17. Crossref, doi:10.1016/j.annonc.2025.08.1511.

Calfa C, Rothe M, Mangat-Dhaliwal P, Garrett-Mayer E, Reynolds C, Wadlow RC, Chen M-TD, Ammakkanavar NR, Pelster M, Pisick E, Butler KY, Crysler O, Thomas CA, Jackson AL, Philip TM, Gregory A, Hinshaw D, Grantham G, Halabi S, Schilsky RL. 942P Atezolizumab plus Talazoparib (A+T) in patients (pts) with solid tumors with non-BRCA1/2 DNA damage repair gene (non-BRCA) mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Annals of Oncology. Elsevier BV; 2025. p. S616–S617.